The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 247-253

  Sturm, Patrick D J ^a   Hruban, Ralph H ^b   Ramsoekh, Teun B ^a   Noorduyn, L Arnold ^a   Tytgat, Guido N J ^a   Gouma, Derk J ^a   Offerhaus, G Johan A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Ampulla of Vater; Bile duct; Carcinoma; Cytology; Diagnosis; K ras; p53; Pancreas

Indexed keywords

DNA; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREATICODUODENECTOMY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VATER PAPILLA CARCINOMA;

AGED; AMPULLA OF VATER; BIOPSY; CODON; GENES, P53; GENES, RAS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031757005     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998110)186:3<247::AID-PATH179>3.0.CO;2-J     Document Type: Article

References (41)

1. Warshaw AL, Fernandez-del Castillo C. Medical progress: pancreatic carcinoma. N Engl J Med 1992; 326: 455-465.
2. Davidson BR. Progress in determining the nature of bile duct strictures. Gut 1993; 34: 725-726.
3. Ponction T, Gagnon P, Berger F, et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc 1995; 42: 565-572.
4. Enayati PG, Traverso LW, Galagan K, et al. The meaning of equivocal pancreatic cytology in patients thought to have pancreatic cancer. Am J Surg 1996; 171: 525-528.
5. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
6. Hruban RH, van Mansfeld ADM, Oferhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554.
7. Chung CH, Wilentz RE, Polak MM, et al. Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 1996; 49: 460-464.
8. Motojima K, Tsunoda T, Kanematsu T, Nagata Y, Urano T, Shiku H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991; 214: 657-662.
9. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gall bladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994; 74: 1542-1545.
10. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gall bladder and bile ducts. Liver 1996; 16: 99-104.
11. DiGiuseppe JA, Hruban RH, Goodman SN. et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101: 684-688.
12. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
13. van Laethem JL, Vertongen P, Deviere J, et al. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut 1995; 36: 781-787.
14. Apple SA, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW. Polymerase chain reaction-base K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996; 105: 321-326.
15. Villanueva A, Reyes G, Cuatrecasas M, et al. Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology 1996; 110: 1587-1594.
16. Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL. Pradayrol L. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191.
17. Iguchi H, Sugano K, Fukayama N. et al. Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 1996; 110: 221-226.
18. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
19. Ishimaru S, Itoh M, Hanada K, Tsuchida A, Iwao T, Kajiyamna G. Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Cancer 1996; 77: 2233-2239.
20. van Es JM, Polak MM, van den Berg FM, et al. Molecular markers for diagnostic cytology of neoplasms in the head of the pancreas - mutation of K-ras and Overexpression of the p53 gene product. J Clin Pathol 1995; 48: 218-222.
21. Klöppel G, Solica E, Longnecker DS, Capella C, Sobin LH. Histological Typing of Tumours of The Exocrine Pancreas. New York; Springer-Verlag, 1996.
22. Jass JR, Sobin LH. Histological Typing of Intestinal Tumours. New York: Springer-Verlag, 1989.
23. Albores-Saavedra J, Jenson DE, Sobin LH. Histological Typing of Tumours of the Gallbladder and Extrahepatic Bile Ducts, New York: Springer-Verlag, 1990.
24. Slebos RJC, Boerrigter L, Evers SG, Wisman P, Mooi WJ, Rodenhuis S. A rapid and simple procedure for the detection of ras mutations in formalinfixed paraffin-embedded tissue. Diagn Mol Pathol 1992; 1: 136-141.
25. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203-2207.
26. Giaretti W, Monaco R, Pujic N, Rapallo A, Nigro S, Geido E. Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas. Am J Pathol 1996; 149: 237-245.
27. Tsao J, Shibata D. Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. Am J Pathol 1994; 145: 531-534.
28. Nagel S, Borisch B, Thein SL, et al. Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers. Cancer Res 1995; 55: 2866-2870.
29. Gorunova L, Johansson B, Dawiskiba S. et al. Massive cytogenetic heterogeneity in a pancreatic carcinoma. Gene Chromosome Canc 1995; 14: 259-266.
30. Jacoby RF, Marshall DJ, Kailas S, Schlack S, Harms B, Love R. Genetic instability associated with adenoma to carcinoma progression in hereditary nonpolyposis colon cancer. Gustroenterology 1995; 109: 73-82.
31. Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147: 92-101.
32. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-231.
33. DiGiuseppe JA, Hruban RH, Offerhaus GJA. et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994; 144: 889-895.
34. Matsubara T, Sakurai Y, Sasayama Y. et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer 1996; 77: 1752-1757.
35. Yanagisawa A, Ohtake K, Ohashi K. et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
36. Cerny WL, Mangold KA, Scarpelli DG. K-ros mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Canter Res 1992; 52: 4507-4513.
37. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979; 43: 1418-1428.
38. Klöppel G, Bommer G, Rückert K, Seifert G. Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis. Virchows Arch A 1980; 387: 221-233.
39. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-3502.
40. Offerhaus GJA. Molecular and epidemiological necropsy: two or a pair? Lancet 1996; 347: 346.
41. Baas IO, van den Berg FM, Mulder JWR. et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 1996; 178: 264-267.